{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T13:25:23Z","timestamp":1756992323473,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["20K16136","19K16505"],"award-info":[{"award-number":["20K16136","19K16505"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s00380-021-01830-1","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T22:02:35Z","timestamp":1616623355000},"page":"1088-1097","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["In vivo characterization of anti-atrial fibrillatory potential and pharmacological safety profile of INa,L plus IKr inhibitor ranolazine using the halothane-anesthetized dogs"],"prefix":"10.1007","volume":"36","author":[{"given":"Yoshio","family":"Nunoi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuichi","family":"Kambayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihoko","family":"Hagiwara-Nagasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koki","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Izumi-Nakaseko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,24]]},"reference":[{"key":"1830_CR1","first-page":"194","volume-title":"Basic and clinical pharmacology","author":"BG Katzung","year":"2018","unstructured":"Katzung BG (2018) Vasodilators & the treatment of angina pectoris. In: Katzung BG (ed) Basic and clinical pharmacology, 14th edn. McGraw-Hill Education, New York, pp 194\u2013211","edition":"14"},{"key":"1830_CR2","doi-asserted-by":"publisher","first-page":"581837","DOI":"10.3389\/fphar.2020.581837","volume":"11","author":"M Geng","year":"2020","unstructured":"Geng M, Lin A, Nguyen TP (2020) Revisiting antiarrhythmic drug therapy for atrial fibrillation: reviewing lessons learned and redefining therapeutic paradigms. Front Pharmacol 11:581837","journal-title":"Front Pharmacol"},{"key":"1830_CR3","first-page":"228","volume-title":"Basic and clinical pharmacology","author":"RD Harvey","year":"2018","unstructured":"Harvey RD, Grant AO (2018) Agents used in cardiac arrhythmias. In: Katzung BG (ed) Basic and clinical pharmacology, 14th edn. McGraw-Hill Education, New York, pp 228\u2013253","edition":"14"},{"key":"1830_CR4","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1161\/CIRCULATIONAHA.118.035455","volume":"138","author":"M Lei","year":"2018","unstructured":"Lei M, Wu L, Terrar DA, Huang CL (2018) Modernized classification of cardiac antiarrhythmic drugs. Circulation 138:1879\u20131896","journal-title":"Circulation"},{"key":"1830_CR5","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1161\/01.CIR.0000139333.83620.5D","volume":"110","author":"C Antzelevitch","year":"2004","unstructured":"Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Corderio JM, Thomas G (2004) Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110:904\u2013910","journal-title":"Circulation"},{"issue":"Suppl 1","key":"1830_CR6","doi-asserted-by":"publisher","first-page":"S169","DOI":"10.1111\/j.1540-8167.2006.00401.x","volume":"17","author":"AI Undrovinas","year":"2006","unstructured":"Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN (2006) Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol 17(Suppl 1):S169\u2013S177","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1830_CR7","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.hrthm.2008.03.018","volume":"5","author":"S Sicouri","year":"2008","unstructured":"Sicouri S, Glass A, Belardinelli L, Antzelevitch C (2008) Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm 5:1019\u20131026","journal-title":"Heart Rhythm"},{"key":"1830_CR8","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/j.1540-8167.2009.01437.x","volume":"20","author":"K Kumar","year":"2009","unstructured":"Kumar K, Nearing BD, Carvas M, Nascimento BCG, Acar M, Belardinelli L, Verrier RL (2009) Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. J Cardiovasc Electrophysiol 20:796\u2013802","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1830_CR9","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1161\/CIRCULATIONAHA.107.724880","volume":"116","author":"BM Scirica","year":"2007","unstructured":"Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CH, Molhoek P, Verheugt FWA, Gersh BJ, McCabe CH, Braunwald E (2007) Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the metabolic efficiency with ranolazine for less ischemia in non ST-elevation acute coronary syndrome thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 116:1647\u20131652","journal-title":"Circulation"},{"key":"1830_CR10","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/europace\/eut407","volume":"16","author":"KC Koskinas","year":"2014","unstructured":"Koskinas KC, Fragakis N, Katritsis D, Skeberis V, Vassilikos V (2014) Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation. Europace 16:973\u2013979","journal-title":"Europace"},{"key":"1830_CR11","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10557-018-6832-8","volume":"32","author":"V Simopoulos","year":"2018","unstructured":"Simopoulos V, Hevas A, Hatziefthimiou A, Dipla K, Skoularigis I, Tsilimingas N, Aidonidis I (2018) Amiodarone plus ranolazine for conversion of post-cardiac surgery atrial fibrillation: enhanced effectiveness in reduced versus preserved ejection fraction patients. Cardiovasc Drugs Ther 32:559\u2013565","journal-title":"Cardiovasc Drugs Ther"},{"key":"1830_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/1060028016673073","volume":"51","author":"CM White","year":"2017","unstructured":"White CM, Nguyen E (2017) Novel use of ranolazine as an antiarrhythmic agent in atrial fibrillation. Ann Pharmacother 51:245\u2013252","journal-title":"Ann Pharmacother"},{"key":"1830_CR13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.23736\/S0026-4725.17.04382-1","volume":"66","author":"R De Vecchis","year":"2018","unstructured":"De Vecchis R, Ariano C, Giasi A, Cioppa C (2018) Antiarrhythmic effects of ranolazine used both alone for prevention of atrial fibrillation and as an add-on to intravenous amiodarone for its pharmacological cardioversion: a meta-analysis. Minerva Cardioangiol 66:349\u2013359","journal-title":"Minerva Cardioangiol"},{"key":"1830_CR14","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1161\/CIRCEP.115.002856","volume":"8","author":"JA Reiffel","year":"2015","unstructured":"Reiffel JA, Camm AJ, Belardinelli L, Zeng D, Karwatowska-Prokopczuk E, Olmsted A, Zareba W, Rosero S, Kowey P, HARMONY Investigators (2015) The HARMONY trial: combined ranolazine and dronedarone in the management of paroxysmal atrial fibrillation: mechanistic and therapeutic synergism. Circ Arrhythm Electrophysiol 8:1048\u20131056","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"1830_CR15","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1038\/bjp.2008.240","volume":"154","author":"A Sugiyama","year":"2008","unstructured":"Sugiyama A (2008) Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br J Pharmacol 154:1528\u20131537","journal-title":"Br J Pharmacol"},{"key":"1830_CR16","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s12012-017-9434-y","volume":"18","author":"Y Motokawa","year":"2018","unstructured":"Motokawa Y, Nakamura Y, Hagiwara-Nagasawa M, Goto A, Chiba K, Lubna NJ, Izumi-Nakaseko H, Ando K, Naito AT, Yamazaki H, Sugiyama A (2018) In vivo analysis of the anti-atrial fibrillatory, proarrhythmic and cardiodepressive profile of dronedarone as a guide for safety pharmacological evaluation of antiarrhythmic drugs. Cardiovasc Toxicol 18:242\u2013251","journal-title":"Cardiovasc Toxicol"},{"key":"1830_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12012-016-9369-8","volume":"17","author":"S Matsukura","year":"2017","unstructured":"Matsukura S, Nakamura Y, Cao X, Wada T, Izumi-Nakaseko H, Ando K, Naito AT, Sugiyama A (2017) Anti-atrial fibrillatory versus proarrhythmic potentials of amiodarone: a new protocol for safety evaluation in vivo. Cardiovasc Toxicol 17:157\u2013162","journal-title":"Cardiovasc Toxicol"},{"key":"1830_CR18","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1253\/circj.72.1003","volume":"72","author":"T Ishizaka","year":"2008","unstructured":"Ishizaka T, Takahara A, Iwasaki H, Mitsumori Y, Kise H, Nakamura Y, Sugiyama A (2008) Comparison of electropharmacological effects of bepridil and sotalol in halothane-anesthetized dogs. Circ J 72:1003\u20131011","journal-title":"Circ J"},{"key":"1830_CR19","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/clpt.2014.155","volume":"96","author":"L Johannesen","year":"2014","unstructured":"Johannesen L, Vicente J, Mason JW, Sanabria C, Waite-Labott K, Hong M, Guo P, Lin J, Sorensen JS, Galeotti L, Florian J, Ugander M, Stockbridge N, Strauss DG (2014) Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil. Clin Pharmacol Ther 96:549\u2013558","journal-title":"Clin Pharmacol Ther"},{"key":"1830_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s12012-020-09612-3","volume":"21","author":"M Hagiwara-Nagasawa","year":"2020","unstructured":"Hagiwara-Nagasawa M, Kambayashi R, Goto A, Nunoi Y, Izumi-Nakaseko M, Takei Y, Matsumoto A, Sugiyama A (2020) Cardiohemodynamic and arrhythmogenic effects of the anti-atrial fibrillatory compound vanoxerine in halothane-anesthetized dogs. Cardiovasc Toxicol 21:206\u2013215","journal-title":"Cardiovasc Toxicol"},{"key":"1830_CR21","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1254\/jjp.88.414","volume":"88","author":"A Sugiyama","year":"2002","unstructured":"Sugiyama A, Hashimoto K (2002) Effects of a typical IKr channel blocker sematilide on the relationship between ventricular repolarization, refractoriness and onset of torsades de pointes. Jpn J Pharmacol 88:414\u2013421","journal-title":"Jpn J Pharmacol"},{"key":"1830_CR22","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/S0735-1097(00)01056-1","volume":"37","author":"SF Nagueh","year":"2001","unstructured":"Nagueh SF, Sun H, Kopelen HA, Middleton KJ, Khoury DS (2001) Hemodynamic determinants of the mitral annulus diastolic velocities by tissue Doppler. J Am Coll Cardiol 37:278\u2013285","journal-title":"J Am Coll Cardiol"},{"key":"1830_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0160-5402(89)90015-6","volume":"22","author":"A Van de Water","year":"1989","unstructured":"Van de Water A, Verheyen J, Xhonneux R, Reneman RS (1989) An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J Pharmacol Methods 22:207\u2013217","journal-title":"J Pharmacol Methods"},{"key":"1830_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2131\/jts.43.183","volume":"43","author":"K Ando","year":"2018","unstructured":"Ando K, Nakamura Y, Hagiwara-Nagasawa M, Harada H, Miyamoto H, Inamura N, Takagi K, Goto A, Chiba K, Lubna NJ, Izumi-Nakaseko H, Naito AT, Sugiyama A (2018) Comparison of electropharmacological effects between terfenadine and its active derivative fexofenadine using a cross-over study in halothane-anesthetized dogs to analyze variability of pharmacodynamic and pharmacokinetic profiles of terfenadine and torsadogenic risk of fexofenadine. J Toxicol Sci 43:183\u2013192","journal-title":"J Toxicol Sci"},{"key":"1830_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1006\/taap.2000.9041","volume":"169","author":"K Chiba","year":"2000","unstructured":"Chiba K, Sugiyama A, Satoh Y, Shiina H, Hashimoto K (2000) Proarrhythmic effects of fluoroquinolone antibacterial agents: in vivo effects as physiologic substrate for torsades. Toxicol Appl Pharmacol 169:8\u201316","journal-title":"Toxicol Appl Pharmacol"},{"key":"1830_CR26","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1253\/circj.66.857","volume":"66","author":"H Yoshida","year":"2002","unstructured":"Yoshida H, Sugiyama A, Satoh Y, Ishida Y, Kugiyama K, Hashimoto K (2002) Effects of disopyramide and mexiletine on the terminal repolarization process of the in situ heart assessed using the halothane-anesthetized in vivo canine model. Circ J 66:857\u2013862","journal-title":"Circ J"},{"key":"1830_CR27","doi-asserted-by":"publisher","first-page":"17969","DOI":"10.1038\/srep17969","volume":"5","author":"A Virsolvy","year":"2015","unstructured":"Virsolvy A, Farah C, Pertuit N, Kong L, Lacampagne A, Reboul C, Aimond F, Richard S (2015) Antagonism of Nav channels and \u03b11-adrenergic receptors contributes to vascular smooth muscle effects of ranolazine. Sci Rep 5:17969","journal-title":"Sci Rep"},{"key":"1830_CR28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jcdr.2013.08.005","volume":"4","author":"Z Liu","year":"2013","unstructured":"Liu Z, Williams RB, Rosen BD (2013) The potential contribution of ranolazine to Torsade de pointes. J Cardio Dis Res 4:187\u2013190","journal-title":"J Cardio Dis Res"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-021-01830-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00380-021-01830-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-021-01830-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T09:09:51Z","timestamp":1622711391000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00380-021-01830-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,24]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1830"],"URL":"https:\/\/doi.org\/10.1007\/s00380-021-01830-1","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"type":"print","value":"0910-8327"},{"type":"electronic","value":"1615-2573"}],"subject":[],"published":{"date-parts":[[2021,3,24]]},"assertion":[{"value":"21 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}